^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Gendicine (rAd-p53 Gene Therapy)

i
Other names: rAd-p53 Gene Therapy, p53 gene therapy, recombinant Ad-p53 anti-cancer injection
Associations
Trials
Company:
Benda Pharma
Drug class:
p53 stimulant
Associations
Trials
over2years
Role of Adenoviruses in Cancer Therapy. (PubMed, Front Oncol)
Gendicine was approved for treatment of squamous cell carcinoma of the head and neck by the Chinese Food and Drug Administration (FDA) agency in 2003 as a first-ever gene therapy product. Oncorine and ONYX-015 are oncolytic adenoviral vectors that have been shown to be effective against some types of cancer...However, the use of adenoviral vectors in gene therapy is limited by several factors such as pre-existing immunity to adenoviral vectors and high immunogenicity of the viruses. Thus, innovative strategies must be continually developed so as to overcome the obstacles of using adenoviral vectors in gene therapy.
Review • Journal • IO biomarker
|
TP53 (Tumor protein P53) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • CSF2 (Colony stimulating factor 2) • CD40LG (CD40 ligand)
|
Gendicine (rAd-p53 Gene Therapy) • Oncorine (recombinant human adenovirus type 5)
4years
Externally-Controlled Systems for Immunotherapy: From Bench to Bedside. (PubMed, Front Immunol)
Immuno-gene therapy approaches have led to the approval of four advanced therapy medicinal products (ATMPs) for the treatment of p53-deficient tumors (Gendicine and Imlygic), refractory acute lymphoblastic leukemia (Kymriah) and large B-cell lymphomas (Yescarta). In the present manuscript, we will review the different inducible, versatile and externally controlled gene delivery systems that have been developed and their applications to the field of immunotherapy. We will highlight the advantages and disadvantages of each system and their potential applications in clinics.
Review • Journal
|
CD19 (CD19 Molecule)
|
Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T) • Imlygic (talimogene laherparepvec) • Gendicine (rAd-p53 Gene Therapy)
4years
Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China. (PubMed, Curr Gene Ther)
To date, Gendicine has been clinically used in China for treatment of cancers other than HNSCC for more than ten years, mainly for patients with advanced or unresectable malignant tumors. However, the establishment of standard treatment regimens using TP53 gene therapy is still needed in order to advance its use in clinical practice.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 expression
|
Gendicine (rAd-p53 Gene Therapy)
almost5years
Investigation on the genomic characterization of uterine sarcoma for rAd-p53 combined with chemotherapy treatment. (PubMed, Hum Gene Ther)
Our results demonstrated that the TP53 signaling pathway plays an important rule in uterine sarcoma tumorigenesis.TP53 and the upstream gene such as CREBBP, LYN, CDKN2A, and JAK2 may be the genomic characterization for rAd-p53 (Gendicine®)combined with chemotherapy in uterine sarcoma. Besides, the average amount of mutated genes from every patient is large.
Journal • Tumor Mutational Burden
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • JAK2 (Janus kinase 2) • CREBBP (CREB binding protein)
|
Gendicine (rAd-p53 Gene Therapy)